MedTrace Logo

The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training

NCT05570708 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-04-14

No results posted yet for this study

Summary

The study investigates two groups of participants of the SÄPT therapist's training starting in October 2022. The overall objective is to investigate the risks and benefits of personal experience (PE) with substance-induced altered states of consciousness for physicians or psychotherapists in the context of a training course for substance-assisted therapy. Specifically, the study aims to assess changes in therapeutic attitude and other factors important in interactions between patients and therapists (such as empathy and cognitive flexibility).

Conditions

  • Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD

Interventions

DRUG

MDMA, LSD, psilocybin

* MDMA per os (2 x 100mg) in a group setting * LSD per os (75 and 150 mcg) in a 1:1 setting * Psilocybin per os (15 mg and 25 mg) in a group setting * Three study days are without drug administration: Participants experience the role of the therapist in a 1:1 setting

Sponsors & Collaborators

  • Swiss Medical Society for Psycholytic Therapy

    collaborator OTHER

  • Felix Mueller

    lead OTHER

Principal Investigators

  • Felix Müller, MD · University of Basel

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
27 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-25
Primary Completion
2029-06-01
Completion
2029-06-01

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05570708 on ClinicalTrials.gov